Study of SNP318 for diabetic macular edema
Part of Eyes & vision clinical trials.
This study tests an investigational drug called SNP318 for people with diabetic macular edema (DME), a condition that causes swelling in the retina and can lead to vision loss. The goal is to see if SNP318 is safe and can improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 or type 2 diabetes, and your blood sugar levels are stable.
- You have diabetic macular edema affecting the center of your retina, with a retinal thickness of at least 320 micrometers.
- Your vision in the study eye is between 25 and 82 letters on an eye chart (roughly 20/40 to 20/320).
- Your vision in the other eye is at least 25 letters on the eye chart.
- You have not had an anti-VEGF injection in the study eye within 90 days before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This study tests whether a medication called dapagliflozin, which is usually used for diabetes and heart failure, can help reduce swelling in the retina (diabetic macular edema) and improve vision. It is for people with type 2 diabetes who are already taking insulin and metformin.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.